Log in or Sign up for Free to view tailored content for your specialty!
Neurology News
Long-term extension studies seek to further evaluate ALZ-801 for Alzheimer’s disease
Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.
FDA grants orphan designation to Fragile X syndrome therapeutic
The FDA has granted orphan drug designation to a small molecule therapeutic for individuals with Fragile X syndrome.
Log in or Sign up for Free to view tailored content for your specialty!
Transition to inebilizumab treatment linked to suppression of NMOSD attacks
In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research published in Frontiers in Neurology.
How doctors learn has changed dramatically
Any doctor seeing patients has had to field questions unrelated to their specialty.
New AAN guidelines: Medication must optimize seizure control, fetal outcomes
For those with epilepsy who may become pregnant and their potential offspring, medications must optimize seizure control as well as outcomes for the fetus, according to new guidelines presented in Neurology.
Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders
Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.
Lack of sleep in childhood increases risk of psychosis in early adulthood
Persistent shorter sleep durations during childhood were associated with a greater risk of psychosis disorder and psychotic episodes during early adulthood, a study in JAMA Psychiatry showed.
Partnership to advance novel therapeutic, drug delivery platform for Parkinson’s disease
A health care innovation company and a clinical-stage biotech company have announced a partnership to advance a novel apomorphine therapeutic in combination with a wearable drug delivery platform to treat Parkinson’s disease.
VIDEO: ‘Clinically significant’ cognitive improvement found with Angelman syndrome drug
DENVER — Treatment with a novel therapeutic led to clinically significant improvement in cognition for young persons with Angelman syndrome, Kemi Olugemo, MD, FAAN, said in this Healio video at the American Academy of Neurology annual meeting.
Having both diabetes, CAD increases risk for dementia
Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read